The Brain-Lung Axis: How the Brain and Lungs Communicate — and Why It Matters for Patients

Table of Contents

• Key Points
• Background: Why Researchers Are Looking at the Brain and Lungs Together
• How This Review Was Conducted
• The Four Communication Channels of the Brain-Lung Axis
• Channel 1: The Lung Microbiome
• Channel 2: Neural Pathways (the Vagus Nerve and Sympathetic System)
• Channel 3: Metabolite Pathways (Substance P, Extracellular Vesicles, and Catecholamines)
• Channel 4: Immune Pathways (Microglia and Inflammation)
• Clinical Implications: Traumatic Brain Injury and the Lungs
• What This Means for Patients
• Limitations: What This Review Could Not Prove
• Recommendations and Practical Takeaways
• Frequently Asked Questions
• Source Information

Key Points

• The brain-lung axis is a two-way link between the central nervous system and the lungs, running through lung microbes, nerve pathways, metabolites, and immune cells.
• A pooled analysis found about 19% of traumatic brain injury patients develop ARDS, typically around 3 days after injury, with a 30% to 40% death rate.
• Severe lung diseases such as ARDS and COPD can worsen brain inflammation and neurological decline, while brain injury can trigger lung damage.
• Much of the evidence comes from animal models, and the review shows associations rather than proving that one condition directly causes the other.
• Blocking substance P receptors reduced neutrophil influx in experiments but also impaired bacterial clearance, so a therapy aimed at this pathway could cause harm as well as benefit.

Background: Why Researchers Are Looking at the Brain and Lungs Together

The human brain keeps complex, ongoing connections with organs throughout the body. Scientists have already established the existence of a gut-brain axis (a two-way communication link between the digestive tract and the brain). Now, growing evidence suggests the brain and lungs do something very similar.

This two-way communication is what researchers call the brain-lung axis — a bidirectional pathway (a route that carries signals in both directions) linking the central nervous system (CNS, meaning the brain and spinal cord) with the respiratory system. When this system goes wrong, it is closely tied to the development and worsening of many diseases.

Communication along this axis runs through four main channels: the lung microbiome (the community of bacteria and other microbes living in the lungs), neural pathways (nerve connections), metabolite signaling (chemical messengers), and immune pathways (the body's defense system).

The consequences run in both directions. Traumatic brain injury (TBI, damage to the brain from a blow or jolt), stroke, and other cerebral disorders can cause lung injury. In the other direction, severe lung conditions such as acute respiratory distress syndrome (ARDS, a sudden and life-threatening form of lung failure) and chronic obstructive pulmonary disease (COPD, a progressive lung disease that makes breathing difficult) can intensify neuroinflammation (inflammation in the brain), worsen brain damage, impair neurological function, and lead to poorer outcomes.

Studying this axis does more than explain how disease progresses. It also reveals possible targets for treatment. The authors argue that this research provides new ways to understand disease mechanisms, develop diagnostic tools, and formulate treatment strategies — and lays the groundwork for therapies that treat more than one organ at a time.

How This Review Was Conducted

This is a review article, which means the authors gathered and interpreted existing published research rather than running a new experiment. Still, they described a specific and reproducible search approach.

The authors searched the PubMed database for publications from 2015 to 2025. They used the following search terms and Boolean operators (commands that combine search words): (((brain) AND (lung)) OR (TBI)) OR (stroke).

To make the search as complete as possible, they did not restrict results by disease mechanism or study design. They expanded the search with synonyms and related keywords — for example, using "traumatic brain injury" in place of TBI and "cerebral infarction" (brain tissue death from lost blood supply) in place of stroke — to improve sensitivity (the chance of catching relevant papers).

They then screened the initial results by title and abstract, focusing on studies that contained information about immune responses or inflammation.

The Four Communication Channels of the Brain-Lung Axis

The authors break the brain-lung axis down into four interacting systems. Each one can carry signals from the brain to the lungs, from the lungs to the brain, or both. Together, they form a network in which microbes, nerves, chemical messengers, and immune cells all influence one another.

Channel 1: The Lung Microbiome

The lungs are not sterile. They host a community of microbes, though far fewer than the gut. The lung microbiome has a relatively low biomass (total microbial mass), with an abundance of roughly 10⁸ colony-forming units per gram (CFU/g). For comparison, gut microbiota reach about 10¹³ to 10¹⁴ CFU/g — roughly 100,000 times denser.

Because the lung's microbial population is comparatively small, even minor external disturbances can be enough to cause dysbiosis (a harmful imbalance in the microbial community).

Anatomy makes the lungs especially vulnerable to sending signals to the rest of the body. The lung sits uniquely within the circulatory system, and the blood-air barrier is remarkably thin. The distance that microbial signaling molecules must travel to reach the bloodstream is much shorter in the lung than in the intestine. This distance is at its absolute minimum in the alveolar region (the tiny air sacs where gas exchange happens): there, the boundary between alveolar epithelial cells and the capillary endothelial layer consists of nothing more than a shared basement membrane. That means a microbe or its products are only one thin layer away from the blood.

In lung disease, the composition, abundance, and functional capacity of the microbiota all change. Studies now show that shifts in the lung microbiome influence how susceptible the brain is to autoimmune inflammation (inflammation caused by the immune system attacking the body's own tissue).

Research in microbial endocrinology (the study of how microbes produce and respond to chemical signals) shows that lung microbes or their metabolic products may translocate — move directly across — the alveolar-capillary barrier. Once in the systemic circulation (the bloodstream), these components can reach the CNS and exert functional effects there.

Several animal and clinical findings support this:

• In Sprague-Dawley rats subjected to controlled cortical impact (a lab technique that deliberately injures the cortex and hippocampus to model TBI), severe TBI caused significant structural changes in the lung microbiome. This included the translocation of gut microbiota into the lungs, which then led to secondary pulmonary infections after severe TBI.
• In a study by Ma and colleagues using a rat model of experimental autoimmune encephalomyelitis (an animal model of multiple sclerosis) with lung involvement, giving the antibiotic neomycin altered the lung microbiome. It also compromised the integrity of both the blood-brain barrier (BBB, the protective filter between the bloodstream and the brain) and the pulmonary endothelial barrier. This was shown by reduced expression of the barrier proteins plasmalemma vesicle associated protein 1 and zona occludens 1. Bacteria then moved from the lungs into the bloodstream, affecting brain function.
• Control of the CNS by lung microbiota appears to work mainly through the pulmonary brain-derived neurotrophic factor (BDNF)-TrkB signaling pathway. Emerging evidence shows that inhaling a TrkB agonist (a substance that activates this receptor) can switch on pulmonary vagal afferents (sensory nerve fibers in the lungs), which suggests a possible treatment for migraine.
• Lu and colleagues found that infecting aged Alzheimer's disease (AD) mice with Gram-negative respiratory pathogens produced marked glial cell activation (activation of the brain's support and immune cells) and β-amyloid deposition (the protein buildup characteristic of Alzheimer's). Infection exposure accelerated AD-related pathological changes and cognitive impairment.
• In people with multiple sclerosis (MS), respiratory viral or bacterial infections can cause pulmonary dysbiosis, which in turn influences inflammatory regulation in MS.
• In mouse models, putting Pseudomonas aeruginosa (a bacterium known to cause pneumonia) into the airways produced anxiety-like behaviors by disrupting the blood-brain barrier. Clinical reports back this up: Pseudomonas aeruginosa infection introduced by an intraventricular catheter (a tube placed into the brain's fluid-filled spaces) has been linked to hospital-acquired postoperative meningitis.

These findings underscore the significant role the lung microbiome plays in nervous system disorders triggered by exposure to environmental pathogens.

Channel 2: Neural Pathways (the Vagus Nerve and Sympathetic System)

Two-way communication along the brain-lung axis is mainly handled by the autonomic nervous system (the part of the nervous system that controls involuntary body functions), with the vagus nerve (parasympathetic, the "rest and digest" branch) and the sympathetic nervous system (the "fight or flight" branch) working together.

Vagal nerve endings are widely distributed throughout the lung tissue. They allow two-way signal transmission through stimulation receptors and tension receptors on sensory nerve fibers. These receptors carry lung signals up to the CNS while also receiving feedback from the CNS to adjust breathing.

Researchers have identified that GABAergic neurons (nerve cells that use the chemical messenger GABA) in the central amygdala (CeA, a brain region involved in emotion and threat response) become strongly activated during severe pneumonia. This contributes substantially to inflammation and lung injury. When investigators inhibited these CeA GABAergic neurons, the pulmonary cytokine storm (an overwhelming, damaging flood of inflammatory signals in the lungs) was reduced and survival rates improved in mouse models of lethal pneumonia.

The pathway linking the CeA to the rostral ventrolateral medulla (a brainstem region that controls sympathetic outflow) and then to sympathetic neurons creates a direct conduit between brain and lungs. This pathway boosts norepinephrine (NE, also called noradrenaline) release and amplifies inflammatory signaling.

Other neural findings include:

• The vagus nerve is linked to allergic conditions such as asthma and COPD, where it drives bronchoconstriction (tightening of the airways) and mucus hypersecretion (excess mucus production).
• The vagus nerve may serve as a highway for pathogens. Viruses infecting the lungs can reach the brainstem respiratory center through the vagus nerve. Bacteria may use similar routes or exploit outer membrane vesicles (small packets that bud off bacteria) to break through the blood-brain barrier.
• Activating pulmonary vagal sensory neurons can trigger serotonin release from the dorsal raphe nucleus (a brainstem area), which reduces depressive behaviors. This suggests a possible therapeutic role for a "pulmonary vagus-brain axis."
• During asthma attacks, the paraventricular nucleus (PVN, a brain region that regulates stress hormones) and the dorsal vagal complex become activated. Oxytocin neurons within the PVN may participate in the development of asthma attacks. When asthma begins, neuron excitation in the PVN generates impulses that reflexively adjust airway hyperreactivity through the medullary respiratory center.
• Vagal ischemia (reduced blood flow to the vagus nerve) caused by subarachnoid hemorrhage (bleeding around the brain) leads to degeneration of vagal axons. This produces an imbalance between the sympathetic and vagal systems and has been implicated in neurogenic pulmonary edema (NPE, fluid buildup in the lungs caused by a brain injury).
• Using resting-state functional MRI (a brain imaging technique that measures activity while a person rests), researchers detected altered activity in the cerebellum, frontal lobe, temporal lobe, occipital lobe, and insular cortex of asthma patients. During acute asthma flares, inflammation stimulates afferent (incoming) fibers of the pulmonary vagus nerve, sending signals to the nucleus tractus solitarius, which then projects to multiple brain regions and alters their functional dynamics.
• In the ongoing inflammation of asthma, increased airway resistance stimulates respiratory reflexes, chemoreceptors, and pulmonary stretch receptors in the airways. The resulting nerve impulses travel up the spinothalamic pathway to the insular cortex and anterior cingulate cortex, with breathing control integrated through connections involving the medial prefrontal cortex and the brainstem.
• Asthma attacks are often accompanied by some degree of hypoxia (low oxygen). Hypoxia causes synaptic degeneration (damage to nerve connections) within the hippocampus, leading to impaired learning, impaired memory, and even cognitive dysfunction.

TBI triggers excessive sympathetic activation, setting off a catecholamine storm (a surge of stress hormones such as adrenaline and noradrenaline). Catecholamines act through α-adrenergic receptors to cause pulmonary vasoconstriction (narrowing of lung blood vessels) and systemic vasoconstriction. This diverts blood volume into the pulmonary circulation and raises pulmonary capillary hydrostatic pressure — the pressure pushing fluid out of the lung's smallest blood vessels.

At the same time, breakdown of the blood-brain barrier lets pro-inflammatory cytokines such as interleukin (IL)-6 and tumor necrosis factor (TNF)-α enter the systemic circulation. These activate lung inflammation and promote cell death (apoptosis), ultimately producing neurogenic pulmonary edema.

Two treatment clues emerge here. Pretreatment with α-adrenergic antagonists (drugs that block these receptors) can reduce lung injury, and beta-blockers improve outcomes in TBI patients.

The authors also describe two competing explanations for how NPE develops. The blast injury theory proposes that a rapid surge in intracranial pressure (pressure inside the skull) damages the alveolar-capillary membrane through a sympathetic storm. The pulmonary venule hypersensitivity theory proposes that isolated pulmonary vasoconstriction alone can also trigger NPE.

Channel 3: Metabolite Pathways (Substance P, Extracellular Vesicles, and Catecholamines)

The neuropeptide (nerve-signaling protein) substance P (SP) is expressed in more than 30 brain regions. When microinjected into the ventrolateral medulla, it increases breathing amplitude while reducing breathing frequency.

In the periphery (outside the brain), substance P contributes to airway inflammation by causing bronchoconstriction and mucosal edema (swelling of the airway lining), giving it a strong association with conditions such as asthma.

After a harmful stimulus such as TBI, vagal afferent neurons secrete substance P. This drives pulmonary vasodilation (widening of lung blood vessels), increased vascular permeability (leakier blood vessels), and the recruitment and migration of neutrophils (a type of infection-fighting white blood cell). Conversely, blocking substance P receptors suppresses neutrophil influx, impairs bacterial clearance, and promotes bacterial pneumonia — an important double-edged finding.

In asthmatic rat models, substance P produced in the hypothalamic paraventricular nucleus not only reflexively adjusts airway and lung activity through the medullary regions, but also influences peripheral airway hyperreactivity by regulating the activity of the hypothalamic-pituitary-adrenal (HPA) axis (the body's central stress hormone system).

Extracellular vesicles (EVs) are a second key messenger. These are heterogeneous membrane structures — including exosomes, microvesicles, and apoptotic bodies — that carry cargo between the brain and lungs in both healthy and diseased states.

Several findings illustrate how they work:

• In mouse models of TBI, brain-derived EVs (including brain-derived microvesicles) transport inflammatory proteins to the lungs. This triggers pyroptosis (a form of inflammatory cell death) in pulmonary endothelial cells, breaks down the alveolar-capillary barrier, and worsens vascular permeability, pulmonary edema, and the infiltration of immune cells and cytokines.
• Blocking the uptake of brain-derived EVs in the lungs reduces pulmonary inflammation.
• EVs carrying inflammasome proteins (molecular platforms that drive inflammation) cause acute lung injury in TBI mouse models. Serum-derived EVs from TBI patients carry inflammasome components, which promote pyroptosis of pulmonary endothelial cells and disrupt barrier integrity, worsening vascular leakage and pulmonary edema.
• High-oxygen (hyperoxic) conditions stimulate release of lung-derived EVs containing inflammasome proteins. These enter the circulation of newborn mice and rats and cause neuroinflammatory injury.
• Preterm infants receiving hyperoxia therapy show significantly elevated levels of apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) inside EVs derived from alveolar macrophages. These ASC-carrying EVs enter the bloodstream, cross the blood-brain barrier, and reach key brain regions such as the hippocampus. In mouse models, they trigger pulmonary inflammation, impaired alveolarization (failure of air sacs to develop properly), and abnormal blood vessel development, while also inducing neuroinflammation, cell death, and activation of pyroptotic and necroptotic pathways. This shows EVs act as inter-organ messengers that carry lung injury signals to the brain — and they are critical mediators in bronchopulmonary dysplasia (a chronic lung disease of premature infants) and the associated brain injury.
• Circulating blood exosomes containing caspase-1 cross the blood-brain barrier, causing neuroinflammation and activation of caspase-1/gasdermin D in newborn rats with ventilator-induced lung injury. This interaction may contribute to brain injury and neurodevelopmental deficits in infants who receive injurious or prolonged mechanical ventilation.
• Both neurons and glial cells release EVs containing bioactive molecules. Once secreted, these regulate synaptic plasticity and activity, neurogenesis (birth of new neurons), myelination (insulation of nerve fibers), and neuronal homeostasis (stable internal balance). These EVs can cross the blood-brain barrier and shape physiological recovery after disease or injury. CNS disorders such as TBI, neurodegenerative diseases, and infections are all marked by neuroinflammation; under these conditions, altered EVs change pathway regulation, microglial responses, and the secretion of pro-inflammatory cytokines, either suppressing or resolving inflammation in the cells that receive them.

Catecholamines provide a third metabolite route. Activation of the sympathetic-adrenomedullary axis (part of the body's stress response) raises plasma levels of catecholamines including epinephrine, norepinephrine, and dopamine. Norepinephrine makes bacteria grow faster, increases bacterial motility (movement), and boosts toxin expression. In other words, stress hormones can make bacteria more dangerous, raising the incidence of pulmonary infections.

In asthma, inflammatory cytokines stimulate the amygdala, which activates the HPA axis. Circulating glucocorticoids (stress hormones such as cortisol) then bind to glucocorticoid receptors on airway epithelial cells and immune cells, adjusting the expression of IL-4, IL-5, and IL-13. This provides a central mechanism for regulating peripheral inflammation.

Channel 4: Immune Pathways (Microglia and Inflammation)

Microglia are the principal immune cells inside the central nervous system. When they receive an inflammatory stimulus, they activate into the M1 phenotype (an aggressive, inflammation-promoting state) and release large amounts of pro-inflammatory mediators.

These mediators damage neurons in several ways. One key mechanism is upregulation of indoleamine 2,3-dioxygenase, an enzyme that diverts tryptophan metabolism away from serotonin production and toward the kynurenine pathway — ultimately leading to neuron death. At the same time, activated microglia interact harmfully with astrocytes (star-shaped brain support cells), making neuroinflammation worse.

Pulmonary dysbiosis has a profound effect on microglia. It causes morphological changes — reduced branching complexity — and makes microglia less responsive to inflammatory signals. The result is reduced recruitment of immune cells to inflamed brain tissue.

Researchers compared differentially expressed genes (genes switched on or off at different levels) in whole brain tissue with those specifically altered in microglia, and found significant overlap. Combining gene ontology analysis (a method for sorting genes by biological function) with quantitative polymerase chain reaction (a lab technique that measures gene activity), they concluded that CNS tissue changes caused by the lung microbiome mainly affect microglial function. This explains how the lung microbiome may be mechanistically involved in brain autoimmune processes and provides new evidence that peripheral organs influence the CNS.

Asthma's oxidative stress (damage from reactive molecules) also modulates Th1/Th2 immune-inflammatory responses (the balance between two arms of the immune system), activates microglia, and promotes release of inflammatory cytokines in brain regions such as the hippocampus through activation of the NF-κB signaling pathway. As a result, levels of N-acetylaspartate (a marker of healthy neuron function) fall in the hippocampus of people with asthma, ultimately leading to cognitive dysfunction.

After lung infection or injury, immune cells release a variety of pro-inflammatory mediators and regulatory factors. Notably, IL-6 induces microglial toll-like receptor 4/Nuclear factor Kappa-light-chain-enhancer of activated B cells (TLR4/NF-κB) signaling during ventilator-induced lung injury, contributing to cognitive impairment, delirium (acute confusion), and neurological harm through systemic inflammatory storms, hypoxemia (low blood oxygen), and iatrogenic injury (harm caused by medical treatment itself, such as mechanical ventilation).

Clinical Implications: Traumatic Brain Injury and the Lungs

TBI frequently causes a range of pulmonary complications, which can progress to ARDS in severe cases. ARDS shows a bimodal distribution (it appears in two distinct patterns or peaks of occurrence) with an incidence of 20%–30% and a mortality rate of 30%–40% — meaning roughly 3 to 4 in every 10 affected patients die.

Research using controlled cortical impact mouse models found that extracellular mitochondria (exMt, mitochondria released outside cells) appear in bronchoalveolar lavage fluid (the fluid obtained by washing the airways) after TBI. These exMt worsen TBI-induced acute lung injury by promoting perivascular accumulation (build-up around blood vessels) and activating pro-inflammatory macrophages that engulf the exMt.

Beyond that, serum factors appearing after injury directly damage the tight junctions in pulmonary endothelial cells, increasing vascular permeability. TBI also causes systemic oxidative stress, producing excessive reactive oxygen species (unstable oxygen molecules that damage cells). Because the lung is a highly perfused organ (it receives a large share of blood flow), it is especially vulnerable to this oxidative damage, which worsens local inflammation and cell death.

TBI also activates the HPA axis, leading to a substantial release of glucocorticoids. At the same time, excitatory amino acids such as glutamate enter the systemic circulation and act directly and harmfully on lung cells, adding to lung injury. Finally, brain injury triggers systemic immunosuppression (a weakened immune response), marked by reduced T cells and natural killer cells, splenic atrophy (shrinking of the spleen), and lymphocyte apoptosis (death of immune cells).

TBI raises susceptibility to lung infections and clinical decline. A prime example is ventilator-associated pneumonia (VAP), a common hospital-acquired lung infection in critically ill patients on breathing machines. Severe TBI patients typically have impaired consciousness and deep immunosuppression, which together raise VAP risk. Comparative analyses show higher VAP frequency in severe TBI patients than in general pediatric intensive care unit populations.

A pooled analysis (a statistical combination of results from multiple studies) found the prevalence of ARDS among TBI patients reaches 19%. That means approximately 1 in every 5 TBI patients develops ARDS, at a median time of 3 days after injury — so half of these cases appear within roughly three days.

What This Means for Patients

The brain-lung axis reframes how clinicians think about critically ill patients. A brain injury is not just a brain injury, and a lung injury is not just a lung injury.

For patients and families, this means:

• Patients with severe TBI, stroke, or other acute brain injury face a real risk of lung complications. About 1 in 5 TBI patients develops ARDS, and ARDS is life-threatening in 30%–40% of cases.
• Patients mechanically ventilated after brain injury are at elevated risk for ventilator-associated pneumonia, especially those with impaired consciousness and weakened immunity.
• Premature infants treated with high oxygen and prolonged mechanical ventilation may face both lung injury and brain injury, because extracellular vesicles carry inflammatory signals from the lungs to the brain.
• People with chronic lung diseases such as asthma and COPD may experience effects that go beyond breathing — including measurable changes in brain activity, memory and learning difficulties, and cognitive dysfunction.
• People with neurological conditions such as Alzheimer's disease and multiple sclerosis may be more vulnerable to worsening when they develop respiratory infections.

Because the same pathways run in both directions, treatments that target this cross-organ communication could potentially help both organ systems at once. The authors note that this field "unveils critical targets for therapeutic intervention" and establishes a theoretical foundation for cross-organ targeted therapies.

Limitations: What This Review Could Not Prove

Several important limitations should be kept in mind when interpreting these findings.

1. Much of the evidence comes from animal models. Many of the mechanisms described — microbiome translocation, central amygdala neuron activation, extracellular vesicle signaling, substance P effects — were demonstrated in rats and mice, including Sprague-Dawley rats, and in mouse models of TBI, asthma, Alzheimer's disease, and pneumonia. Findings in animals do not always transfer directly to humans.
2. This is a review, not a new clinical trial. The authors searched PubMed for publications from 2015 to 2025 and synthesized existing evidence. No new patients were enrolled and no new treatment was tested here.
3. Some human evidence is observational or from case reports. For example, the link between Pseudomonas aeruginosa and hospital-acquired postoperative meningitis is supported by clinical reports rather than controlled trials.
4. Causality is often unclear. The review shows associations — lung dysbiosis with brain autoimmune processes, asthma with altered brain activity — but association does not prove that one directly causes the other.
5. Several proposed theories remain unproven. The blast injury theory and the pulmonary venule hypersensitivity theory are competing explanations for neurogenic pulmonary edema, and the review presents them as theories rather than settled facts.
6. One mechanism has a double edge. Blocking substance P receptors reduces neutrophil influx into the lungs, but it also impairs bacterial clearance and can promote bacterial pneumonia — meaning a therapy aimed at this pathway could cause harm as well as benefit.

Recommendations and Practical Takeaways

The review does not offer direct clinical guidance for individual patients, but several practical implications follow from its findings. Patients and caregivers should treat these as discussion points for conversations with their own medical teams, not as self-directed medical advice.

1. Take respiratory infections seriously in people with neurological conditions. The review links respiratory infections to accelerated Alzheimer's disease pathology and cognitive impairment in animal models, and to worsened inflammatory regulation in multiple sclerosis. Preventing and promptly treating respiratory infections is a reasonable priority in these groups.
2. Monitor lungs closely after brain injury. Because ARDS appears in about 19% of TBI patients and typically around 3 days after injury, early monitoring in this window matters.
3. Recognize that sedation and ventilation decisions have two-organ consequences. Prolonged or injurious mechanical ventilation may send inflammatory signals to the brain, particularly in newborns. Minimizing unnecessary ventilator exposure, where clinically possible, may protect both organs.
4. Consider cognitive symptoms in chronic lung disease. Asthma is associated with reduced N-acetylaspartate in the hippocampus and with cognitive dysfunction. Reporting memory or concentration problems to a clinician is worthwhile for people with chronic asthma or COPD.
5. Ask about medication effects on both systems. The review notes that α-adrenergic antagonists reduced lung injury in experiments and that beta-blockers improved outcomes in TBI patients — suggesting that cardiovascular and neurological medications may affect the brain-lung axis. Individual medication decisions should always come from a treating clinician.
6. Support research into cross-organ therapies. The authors emphasize that exploring the brain-lung axis could improve diagnostic methods, refine treatment strategies, and enhance patient outcomes across respiratory and neurological disorders.

Frequently Asked Questions

What is the brain-lung axis?

The brain-lung axis is a two-way communication system linking the brain and spinal cord with the lungs. It runs through four channels: the lung's resident microbes, nerve pathways, signaling molecules called metabolites, and immune cells. Problems in this system are tied to the development and worsening of many diseases in both organs.

Can a brain injury such as a stroke or TBI cause lung damage?

Yes. A brain injury such as traumatic brain injury or stroke can trigger lung damage, including ARDS. Brain injury also sets off a stress-hormone surge that narrows lung blood vessels and raises pressure in them, and it can let inflammatory signals reach the lungs, producing fluid buildup called neurogenic pulmonary edema.

Can lung disease affect the brain?

Yes. Severe lung conditions such as ARDS and COPD can intensify inflammation in the brain, worsen brain damage, and impair neurological function. Asthma has been linked to altered brain activity and to memory and learning difficulties. In animal models, respiratory infections accelerated Alzheimer's-related changes and cognitive impairment.

Why are premature infants on high oxygen or prolonged ventilation at risk?

High-oxygen conditions stimulate release of lung-derived extracellular vesicles carrying inflammatory proteins. In newborn mice and rats these enter the bloodstream, cross into the brain, and cause neuroinflammation and cell death. Preterm infants on hyperoxia therapy show elevated levels of these vesicle proteins, and prolonged mechanical ventilation may send similar signals to the brain.

Does this research change how my condition is treated now?

Not directly. Much of the evidence comes from animal models, and the review offers no clinical guidance for individual patients. Its findings are discussion points for your own medical team. For example, it notes that alpha-adrenergic antagonists reduced lung injury in experiments and beta-blockers improved outcomes in TBI patients, but medication decisions must come from a treating clinician.

My father had a severe traumatic brain injury — when should we seek a second opinion about his risk of ARDS and lung complications?

About 19% of traumatic brain injury patients — roughly 1 in 5 — develop ARDS, typically around 3 days after injury, and ARDS carries a death rate of 30%–40%. Because lung complications can appear in that early window, a second opinion can be useful when reviewing whether lung monitoring, ventilation decisions, and infection prevention are matched to this two-organ risk. A review of imaging, ventilator settings, and records by an independent expert can clarify whether the current plan addresses both brain and lung injury. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original Article Title: The brain-lung axis: Bridging neurological and respiratory disorders via neural-immune-microbial dialogue.

Journal: Chinese journal of traumatology = Zhonghua chuang shang za zhi

License: CC BY (open access)

Authors: Yang W, Shi X, Xie L, Zhang H, Shen L, Pan L, Feng S, Mao X, Wu X.

Author Affiliations: Department of Neurosurgery and Department of Emergency, The First Affiliated Hospital of Anhui Medical University, Hefei, China; Innovation and Entrepreneurship Laboratory for College Students, Anhui Medical University, Hefei, China; and Department of General Practice, Peking University Third Hospital, Beijing, China.

Publication: Chinese Journal of Traumatology, Volume 29 (2026), pages 235–244. Published by Elsevier B.V. on behalf of the Chinese Medical Association. DOI: https://doi.org/10.1016/j.cjtee.2025.10.006. Received 2 September 2025; revised 29 October 2025; accepted 31 October 2025; available online 5 February 2026.

Article Type: Review article. Open access under a CC BY license.

This patient-friendly article is based on peer-reviewed research.